Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084801 | 0.77 | ALDH1A1 (0.35) | CYP11B2BACE1ALDH1A1 | |
| SCHEMBL25004524 | 0.72 | SLC6A4 (0.38) | PGRABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL29725673 | 0.70 | ABCC9 (0.37) | PGRCYP11B1CYP11B2ABCC9ABCC8 | |
| SCHEMBL28777283 | 0.70 | ABCC9 (0.37) | PGRCYP11B1CYP11B2ABCC9ABCC8 | |
| SCHEMBL31734535 | 0.70 | PTP4A3 (0.38) | PGRABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL3712044 | 0.69 | CYP11B1 (0.51) | PGRCYP11B1CYP11B2ABCC9ABCC8 | |
| SCHEMBL14498539 | 0.67 | ABCC9 (0.39) | PGRABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL18348160 | 0.67 | PGR (0.44) | PGRCYP11B1CYP11B2ABCC9ABCC8 | |
| SCHEMBL2084565 | 0.67 | CYP11B1 (0.36) | PGRCYP11B1CYP11B2ABCC9ABCC8 | |
| SCHEMBL12668434 | 0.67 | PLA2G7 (0.34) | CYP11B1CYP11B2ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | claimed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | claimed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | claimed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | claimed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | MIF, CCL2, CCL11 | PGR 2437/4885CYP11B1 368/4885CYP11B2 424/4885 |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | MIF, CCL2, CCL11 | PGR 2437/4885CYP11B1 368/4885CYP11B2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.